Diabetic Peripheral Neuropathy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Diabetic Peripheral Neuropathy – Pipeline Review, H2 2017’, provides an overview of the Diabetic Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy

The report reviews pipeline therapeutics for Diabetic Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Peripheral Neuropathy therapeutics and enlists all their major and minor projects

The report assesses Diabetic Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics Inc

Celgene Corp

Commence Bio Inc

Grunenthal GmbH

Immune Pharmaceuticals Inc

KPI Therapeutics Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Novaremed Ltd

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

ViroMed Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Peripheral Neuropathy - Overview

Diabetic Peripheral Neuropathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Peripheral Neuropathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Celgene Corp

Commence Bio Inc

Grunenthal GmbH

Immune Pharmaceuticals Inc

KPI Therapeutics Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Novaremed Ltd

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

ViroMed Co Ltd

Diabetic Peripheral Neuropathy - Drug Profiles

(amitriptyline + ketamine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AAD-2004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atexakin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNV-222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNV-2197944 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-32 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRD-135SE1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDA-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirenzepine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium nitrite SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Peripheral Neuropathy - Dormant Projects

Diabetic Peripheral Neuropathy - Discontinued Products

Diabetic Peripheral Neuropathy - Product Development Milestones

Featured News & Press Releases

Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Achelios Therapeutics Inc, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Celgene Corp, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Commence Bio Inc, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Grunenthal GmbH, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Immune Pharmaceuticals Inc, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by KPI Therapeutics Inc, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Medifron DBT Co Ltd, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Novaremed Ltd, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Reata Pharmaceuticals Inc, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by Relief Therapeutics Holding AG, H2 2017

Diabetic Peripheral Neuropathy – Pipeline by ViroMed Co Ltd, H2 2017

Diabetic Peripheral Neuropathy – Dormant Projects, H2 2017

Diabetic Peripheral Neuropathy – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports